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data consist, amongst others, of Diagnostic Related
Groups (DRG), severity of illness, risk of mortality,
number of procedures and comorbidity. Regression
analysis was used to estimate the impact of these pathol-
ogy-related parameters on the use of resources for
medical imaging. RESULTS: All pathology-related 
parameters have a statistically signiﬁcant impact on 
the consumption of medical imaging. Fifty-seven and
three–tenths percent of the case wise variation in utilisa-
tion of resources can be explained by the different para-
meters. However, the interaction of DRG with the
severity of illness in itself explains 46.7% of this varia-
tion. CONCLUSIONS: Pathology-related parameters,
especially the interaction of DRG with the severity of
illness, can be used to determine a lump sum fee that
could partly (+/-50%) replace the in essence fee for
service based payment system currently in practice.
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OBJECTIVE: This paper compares the prices of top
selling generic drugs in Canada with prices for compara-
ble generic products in the United States. METHODS:
The research examined the prices of 27 top selling (in
2001) generic prescription medicines in Canada that were
marketed in both Canada and the United States. The
sample represented approximately 36% of total generic
sales in Canada. For each of the generic medicines a 
representative presentation (strength/dosage form) was
selected—generally the top selling presentation of the
medicine. The prices were the Q1 2002 Canadian ex-
factory prices as listed in the Québec provincial govern-
ment formulary and the US Federal Supply Schedule (FSS)
prices. These prices generally represent the best available
prices in the two countries. RESULTS: Preliminary results
indicate that of the 27 leading generic drug products
examined, 21 had higher prices in Canada than in the
U.S. By all measures Canadian generic prices of the
sample drugs were higher than those in the U.S.: Mean:
+155%; Weighted Mean: +37%; Median +51%. Annual
savings in excess of C$150 million would result if 
Canadians had access to FSS prices for the sample drugs.
If the price differences seen in the sample can be extrap-
olated to all generic drugs available in Canada, the poten-
tial annual savings would exceed C$400 million.
CONCLUSIONS: It is generally accepted that the ex-
factory prices of innovator (brand name) prescription
drugs are signiﬁcantly lower in Canada than in the United
States. It was therefore surprising to ﬁnd the opposite
result for generic drugs. Several factors may contribute to
higher Canadian generic prices. The Canadian generic
industry is highly concentrated (relative to the US) with
the market dominated by two large generics ﬁrms. Sec-
ondly, provincial government reimbursement policies dis-
courage discounting and feature published formularies
that typically establish ex-factory prices for all classes of
customer.
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OBJECTIVES: Spanish Health Administration has devel-
oped some regulatory actions to check the growth of
drugs expenditure. Speciﬁcally, in 1999, Government
approved a reference price system for many drug groups
(homogeneous). Here, we present the initial data from a
study of drug consumption and a estimation of the saving
with the prescriptions of generic drugs. METHODS:
This study was divided into 2 periods: 1990–1998 and
1999–2002. In the second, the inﬂuence of the reference
price system implementation will be observed. Data from
Spanish NHS about drug consumption were provided by
the Ministry of Health and Consumer Affairs. We elabo-
rated our own database. Consumption was expressed as
PVP (price for sale direct to costumer, tax-free) by means
of PTAM (Peseta Millions) or €M (Euro Millions), and
was revised through CPI (Consumption Price Indexes,
Base 1990). Information about PVP drugs was obtained
from Ofﬁcial Drug Directory. DID (Dose for thousand
inhabitants and for day) was also calculated according to
DDD’s standard—Nordic Council Medicines ATC/DDD,
edition 1998. Saving estimation was calculated through
PVP minimum criteria of prescription, since the reference
price system had not been implemented yet. RESULTS:
According to consumption data obtained, in 1998, top
four therapeutic groups—29 active principles—explained
almost 34% of the whole expense—286116.2 PTAM or
2458.33 €M. Besides, if the criterion of PVP minimum
was applied, for the most usual format (package) per pre-
scription, the average saving would be almost 7%. In the
Spanish pharmaceutical market there are many prices for
speciﬁc active principles, being possible to identify the
biggest individual saving. CONCLUSIONS: Almost the
third part of NHS pharmaceutical budget in 1998 was
assigned at 29 active principles. The level of individual
saving was signiﬁcant in omeprazole (44%) or famotidine
(40%), among others.
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Nonadherence (noncompliance) to drug therapy can
result in increased rates of relapse, morbidity, and mor-
tality. Its overall economic impact has been estimated at
$8 billion annually in Canada, and $80 billion in the US,
including both direct and indirect costs. OBJECTIVES:
The purpose of this study was to estimate the economic
burden of hospital admissions due to patient nonadher-
ence in Canada from the viewpoint of the provincial min-
istries of health. METHODS: We estimated the overall
burden in two steps, using a modeling approach. First,
we estimated the impact of nonadherence on hospital
admissions. We performed a random-effects meta-analy-
sis of the published literature to derive an average rate of
hospital admissions due to nonadherence. We then quan-
tiﬁed the resources in monetary terms in Canadian dollars
(CAD). We used utilization and costing data from Statis-
tics Canada on hospitalizations. Various sensitivity analy-
ses were performed with different costing sources for
hospitalizations, such as the Ontario Case Cost Project
and the Ontario Hospital Statistics. RESULTS: We
included 15 studies on nonadherence related hospital
admissions, with a total of 6,144 subjects, to derive an
overall meta-analytic average admission rate of 5.4% (SE
= 0.8%), and 5.2% (SE = 1.1%) for medication under-
use. Applying an average length of stay of 10 days for
10,272 hospital separations per 100,000 population in
Canada, we estimated the 5.4% assumed to be due to
nonadherence to amount to CAD $1,018 million annu-
ally. Sensitivity analysis results ranged from CAD $678
million to CAD $1,633 million annually. CONCLU-
SION: Our results illustrate the extent of the economic
burden of hospitalization due to nonadherence in
Canada. Further studies are warranted for estimating
overall resource use and productivity loss due to 
nonadherence.
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OBJECTIVE: The evidenced-based study tests the
hypotheses (i) National Health Insurance Expenditure
increases with closeness to death (ii) National Health
Insurance Expenditure decreases with age. This study
analysis age, sex and health expenditure differences
before the day of death for one-year period during 1999
and 2000. METHODS: In Taiwan the National Health
Insurance Program had covered 97% population. The
claim data were obtained from Bureau of National Health
Insurance (in 1999 and 2000), the vital registration data
(in 2000) were from Department of Health in Taiwan.
Use the vital registration ID number to merge the
National Health Insurance Expenditure, then retrospect
1 day, 2–7 days, 8–14 days, 15–30 days, 31–60 days,
61–90 days, 91–180 days, 181–270 days, and 271–365
days before dying. RESULTS: The 22.1% dead people
had no medical expenditure in the last year of life. The
expenditure of last year of life accounts for 12.8% of all
National Health Insurance Expenditure, 2.6% of it on
ambulatory care, (1.1% for female, 1.5% for male), and
10.3% of it on inpatient care (3.9% for female, 6.39%
for male), respectively. The expenditure 91–180 days
before death accounts for 18.1% (highest) total expendi-
ture of the last year of life, the lowest is 1 day before
death accounts for 2.3%. The total expenditure for the
age groups 0–64, 65–84, and 85+ accounts for 36.5%,
54.2% and 9.3%, respectively. The total expenditure
ascending with age from 27 years-old (0.11%) to 76
years-old (3.3%) then decreasing with each age. But the
last year expenditure proportion to all year expenditure
is ascending from 27 years old with age. The average
expenditure is $8,307 US dollars per decedents, 26.1
times for average expenditure for each person.
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OBJECTIVES: Guidelines for costing of health services
recommend the use of costs of several providers in
forming a variable used to measure unit cost. In the 
Canadian national list of provincial costs hospital costs
were aggregated by all hospitals within each province and
were compared between provinces. In this paper we val-
idate the provincial cost measure, using data from 
Manitoba hospitals. METHOD: The conceptual measure
for our analysisis the Cost per Weighted case (CWC),
which is equal to the total inpatient costs divided by total
weighted cases. The actual (published) measure of CWC
was not audited for standardization; it was compared
with a revised measure, which was adjusted following an
assessment exercise. The revised measure was based on
the following standardization criteria: (1) the measure of
total cost should include all relevant resources used and
appropriately allocated and (2) weighted cases should
reﬂect the year in which costs were measured. Adjust-
ments were made using data from each hospital: inpatient
costs were based on provincially reported costs according
to a Management Information System (MIS) coding
system and weighted cases were based on the Case Mix
Group measure of the Canadian Institute for Health
Information. RESULTS: Of the 38 hospitals reporting
data, 7 (18%) reported a change in CWC of >10%, 16
reported an adjustment of <10%, and 15 reported no
adjustment. The overall change in CWC was substantial:
of those hospitals with conﬁrmed data, the mean adjusted
CWC was $4538 compared with an adjusted value of
$2195. CONCLUSIONS: The large adjustment in CWC
occurred in only a few hospitals, yet it substantially
changed the overall CWC, which would serve as a stan-
dard value for economic studies. It is necessary to vali-
